Drugs & Targets FDA has accepts Genentech’s BLA for a subcutaneous formulation of rituximab in blood cancer indications November 11, 2017Vol.42 No.42
Drugs & Targets Alecensa gets FDA approval for ALK-positive metastatic NSCLC November 10, 2017Vol.43 No.42
Drugs & Targets FDA approves first treatment for Erdheim-Chester Disease November 10, 2017Vol.43 No.42
Drugs & Targets FDA approves Adcetris for cutaneous anaplastic large cell lymphoma November 10, 2017Vol.43 No.42
Drugs & Targets Seattle Genetics submits sBLA for Adcetris in Hodgkin lymphoma November 10, 2017Vol.43 No.42
Drugs & Targets FDA approves Kite’s CAR-T cell therapy; another win for NCI’s intramural program November 07, 2017Vol.40 No.09By Matthew Bin Han Ong
Drugs & Targets FDA approves AstraZeneca’s Calquence for mantle cell lymphoma November 03, 2017Vol.43 No.41
Drugs & Targets Consortium aims to accelerate preclinical cancer drug discovery November 03, 2017Vol.43 No.41
Drugs & Targets FDA accepts Genentech’s application for Avastin for advanced ovarian cancer October 27, 2017Vol.43 No.40
